Tag: AbbVie

AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The “new” Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

EU Approved Two New Imbruvica Uses

European regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of the blood cancer drug. Johnson & Johnson’s pharma unit said the Europea...

R-Pharm Starting Production of Abbvie’s Sevoran Analog

R-pharm
Russian drugmaker R-Pharm is expanding its line of generics of original drugs by starting production of an analog of Sevoran (sevoflurane), which is an anesthetic produced by the US biopharma company ...

AbbVie Acquired Mavupharma Enhancing Early Stage Oncology Pipeline

AbbVie announced that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for ...

AbbVie to Acquire Allergan for $63bn

AbbVie Inc. and Allergan plc announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transactio...

AbbVie Agreed with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®

abbvie
AbbVie, a global, research and development-driven biopharmaceutical company, announced that Ontario is the first province to reimburse VENCLEXTA® (venetoclax) monotherapy under its Drugs and Devices D...

VENCLEXTA® Received FDA Approval

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) fo...

AbbVie and Boehringer Ingelheim Resolve HUMIRA® U.S. Patent Litigation

patents
AbbVie announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant Boehringer Ingelheim a non-exclusive lice...

All HCV Genotypes Drug Approved for Children

The U.S. Food and Drug Administration approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously ap...

AbbVie Received EC Approval of Skyrizi

AbbVie has announced that the European Commission (EC) has approved its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab), for the treatment of moderate to severe plaque psoriasis in adult patie...

AbbVie’s SKYRIZI™ Approved by FDA

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved SKYRIZI™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor, for th...

BioArctic Started Clinical Study for Parkinon’s Treatment

BioArctic AB announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in healthy volunteers wil...

Fifth BTD for AbbVie and Genentech Drug

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in c...

CHMP’s Positive Opinion for AbbVie Med

CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission....

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

AbbVie and Voyager to Develop Treatment of Parkinson’s

AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, annou...

Priority Review for AbbVie’s NDA

abbvie office
AbbVie, a research-based global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for upadacitin...